SRP3178
TPO human
Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Sinónimos:
MGDF, Megakaryocyte colony-stimulating factor, Thrombopoietin, c-MPL Ligand
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
NACRES:
NA.32
UNSPSC Code:
12352202
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarlebiological source
human
recombinant
expressed in E. coli
assay
≥98% (HPLC), ≥98% (SDS-PAGE)
form
lyophilized
potency
≤1.0 ng/mL ED50
mol wt
18.6 kDa
packaging
pkg of 10 μg
technique(s)
cell culture | mammalian: suitable
impurities
<0.1 EU/μg endotoxin, tested
color
white
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... THPO(7066)
General description
Thrombopoietin (TPO) is a lineage specific growth factor, produced in the liver, kidney and skeletal muscle. It is an acidic glycoprotein. The gene encoding it is localized on human chromosome 3q27.1. Recombinant human TPO is a fully biologically active 174 amino acid polypeptide (18.6kDa), which contains the erythropoietin-like domain of the full length TPO protein.
Biochem/physiol Actions
Thrombopoietin (TPO) stimulates the proliferation and maturation of megakaryocytes, and promotes increased circulating levels of platelets in vivo. TPO signals through the cellular proto-oncogene (c-mpl) receptor and acts as an important regulator of circulating platelets. High levels of TPO have been observed in patients with aplastic anemia. Human and murine TPO exhibits cross-species reactivity.
Physical form
Lyophilized from 0.1% TFA.
Preparation Note
Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a stabilizer (example 5% Trehalose) and store in working aliquots at -20°C to -80°C.
Other Notes
SPAPPACDLR VLSKLLRDSH VLHSRLSQCP EVHPLPTPVL LPAVDFSLGE WKTQMEETKA QDILGAVTLL LEGVMAARGQ LGPTCLSSLL GQLSGQVRLL LGALQSLLGT QLPPQGRTTA HKDPNAIFLS FQHLLRGKVR FLMLVGGSTL CVRRAPPTTA VPSRTSLVLT LNEL
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Kuter, D.J., et al.
Cytokine Reference, 965-982 (2001)
Pancreatic Cancer Cells Induce MicroRNA Deregulation in Platelets.
D?-az-Blancas, et al.
International Journal of Molecular Sciences, 23 (2022)
Jiaxin Zhao et al.
Arteriosclerosis, thrombosis, and vascular biology, 41(10), 2523-2537 (2021-08-06)
Objective: Roxadustat is a new medication for the treatment of renal anemia. EPO (erythropoietin)-the current treatment standard-has been reported to enhance platelet activation and production. However, to date, the effect of roxadustat on platelets is unclear. To address this deficiency